Tolerability of ADXS11-001 Lm-LLO Listeria-Based Immunotherapy With Mitomycin, Fluorouracil, and Radiation for Anal Cancer

Abstract

Toobtain safety and preliminary efficacy data of the combination of ADXS11-001, live attenuated Listeria monocytogenes bacterium, with mitomycin, 5-fluorouracil (5-FU), and intensity modulated radiation therapy in locally advanced anal cancer. Eligibility included patients with previously untreated, nonmetastatic anal cancer with a primary tumor >4cm or node-positive disease. Patients received 2 cycles of mitomycin and 5-FU concurrent with 54.0Gy intensity modulated radiation therapy. One intravenous dose of ADXS11-001 (1×109colony-forming units) was administered before chemoradiation; 3 additional monthly doses were given after chemoradiation. Ten patients were treated, including 1 with N2 and 4 with N3 disease. Two patients had grade 3 acute toxicities after the initial dose of ADXS11-001, including chills/rigors (n=2), back pain (n=1), and hyponatremia (n=1). All ADXS11-001 toxicities occurred within 24hours of administration. There was no apparent increase in chemoradiation toxicities or myelosuppression. One patient had a grade 5 cardiopulmonary event shortly after beginning 5-FU treatment. All 9 assessable patients had complete clinical responses by sigmoidoscopy. Eight of 9 patients (89%) are progression-free at a median follow-up of 42months. Preliminary data show that ADXS11-001 can be safely administered with standard chemoradiation for anal cancer. Further studies of listeria-based immunotherapy with radiation are warranted.